BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,771,897 | +11.5% | 2,368,912 | +10.8% | 0.04% | +13.2% |
| Q2 2023 | $15,048,788 | -18.1% | 2,137,612 | -3.0% | 0.04% | -19.1% |
| Q1 2023 | $18,370,618 | -18.8% | 2,202,712 | +11.8% | 0.05% | -25.4% |
| Q4 2022 | $22,626,070 | -10.9% | 1,970,912 | -2.2% | 0.06% | -14.9% |
| Q3 2022 | $25,399,000 | +15.2% | 2,015,812 | -3.2% | 0.07% | +17.5% |
| Q2 2022 | $22,042,000 | -23.5% | 2,083,412 | +17.6% | 0.06% | -18.2% |
| Q1 2022 | $28,797,000 | -3.4% | 1,771,012 | -17.7% | 0.08% | +2.7% |
| Q4 2021 | $29,804,000 | +8.0% | 2,151,912 | +12.0% | 0.08% | +4.2% |
| Q3 2021 | $27,605,000 | +146.6% | 1,921,012 | +171.3% | 0.07% | +140.0% |
| Q2 2021 | $11,195,000 | +391.0% | 708,112 | +215.8% | 0.03% | +400.0% |
| Q1 2021 | $2,280,000 | -76.6% | 224,212 | -82.9% | 0.01% | -76.9% |
| Q4 2020 | $9,757,000 | +50.3% | 1,309,712 | -30.7% | 0.03% | +36.8% |
| Q3 2020 | $6,490,000 | -35.7% | 1,889,312 | -10.8% | 0.02% | -36.7% |
| Q2 2020 | $10,096,000 | +215.5% | 2,118,812 | +32.4% | 0.03% | +150.0% |
| Q1 2020 | $3,200,000 | -38.2% | 1,599,912 | +6.5% | 0.01% | 0.0% |
| Q4 2019 | $5,181,000 | +106.7% | 1,501,812 | +71.7% | 0.01% | +100.0% |
| Q3 2019 | $2,507,000 | +50.5% | 874,912 | +99.0% | 0.01% | +50.0% |
| Q2 2019 | $1,666,000 | +5.6% | 439,612 | +126.8% | 0.00% | 0.0% |
| Q1 2019 | $1,578,000 | +18.2% | 193,812 | +17.2% | 0.00% | 0.0% |
| Q4 2018 | $1,335,000 | -11.7% | 165,412 | -16.5% | 0.00% | 0.0% |
| Q3 2018 | $1,512,000 | +55.9% | 198,212 | +17.1% | 0.00% | +33.3% |
| Q2 2018 | $970,000 | +117.0% | 169,212 | +80.4% | 0.00% | +200.0% |
| Q1 2018 | $447,000 | -3.7% | 93,800 | -0.6% | 0.00% | 0.0% |
| Q4 2017 | $464,000 | +3.6% | 94,400 | +10.4% | 0.00% | 0.0% |
| Q3 2017 | $448,000 | +26.9% | 85,500 | +34.6% | 0.00% | 0.0% |
| Q2 2017 | $353,000 | +38.4% | 63,512 | +108.8% | 0.00% | 0.0% |
| Q1 2017 | $255,000 | +13.8% | 30,412 | +32.7% | 0.00% | -50.0% |
| Q3 2014 | $224,000 | -70.5% | 22,912 | -61.6% | 0.00% | -66.7% |
| Q2 2014 | $760,000 | – | 59,612 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $44,153,847 | 52.00% |
| ORACLE INVESTMENT MANAGEMENT INC | 585,194 | $6,718,027 | 5.60% |
| Fairmount Funds Management LLC | 2,543,107 | $29,194,868 | 4.63% |
| Saturn V Capital Management LP | 340,163 | $3,751,030 | 3.11% |
| TANG CAPITAL MANAGEMENT LLC | 1,450,000 | $16,646,000 | 2.42% |
| Avoro Capital Advisors LLC | 9,050,000 | $103,894,000 | 1.55% |
| AlphaCentric Advisors LLC | 125,000 | $1,435,000 | 1.42% |
| Sarissa Capital Management LP | 980,288 | $11,253,706 | 1.34% |
| Ghost Tree Capital, LLC | 225,000 | $2,583,000 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 272,173 | $3,124,546 | 0.89% |